POS0480

Guselkumab Response and Inhibition of Structural Damage Progression in Active Psoriatic Arthritis Across APEX Participant Subgroups

Philip J. Mease,[1,2] Christopher T. Ritchlin,[3] Laura C. Coates,[4] Alexa P. Kollmeier,[5] Bei Zhou,[6] Yusang Jiang,[6] Karen Bensley,[6] Koeun Im,[7] Rattandeep Batra,[8] Karissa Lozenski,[9] Soumya D. Chakravarty,[9,10] Proton Rahman,[11] Désirée van der Heijde[12]

[1]Rheumatology Research, Providence Swedish Medical Center, Seattle, WA, USA; [2]University of Washington School of Medicine, Seattle, WA, USA; [3]Department of Medicine, Allergy/Immunology and Rheumatology, University of Rochester Medical Center, Rochester, NY, USA; [4]Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Botnar Research Centre, Oxford, UK; [5]Johnson & Johnson, San Diego, CA, USA; [6]Johnson & Johnson, Spring House, PA, USA; [7]Johnson & Johnson, Cambridge, MA, USA; [8]Johnson & Johnson, Toronto, Canada; [9]Johnson & Johnson, Horsham, PA, USA; [10]Drexel University College of Medicine, Philadelphia, PA, USA; [11]Craig L Dobbin Genetics Research Centre, Faculty of Medicine, Division of Rheumatology, Memorial University of Newfoundland, St. Johns, NL, Canada; [12]Leiden University Medical Center, Leiden, The Netherlands

Scan the QR code. The QR code is intended to provide scientific information for individual reference, and the information should not be altered or reproduced in any way.

Property of Johnson & Johnson and is not for promotional use. Material is distributed for scientific purposes only.

Key Takeaways

- **GUS-treated biologic-naïve pts with active and erosive PsA demonstrated significantly greater clinical improvement and significant inhibition of structural damage progression vs PBO at W24**
- **GUS effects were generally consistent across diverse subgroups of pts defined by baseline demographics, disease characteristics, medication use, and radiographic features of interest**
  - Benefit in ACR20/50 clinical improvement was similar regardless of sex, BMI, PsA duration, joint involvement, CRP, and MTX use at baseline
  - Inhibition of radiographic progression observed across clinical and radiographic feature subgroups

Background

Guselkumab (GUS), a fully-human monoclonal antibody able to bind to the CD64-receptor and simultaneously inhibit the IL-23p19 subunit, is indicated for moderate-to-severe plaque psoriasis, active psoriatic arthritis (PsA), and moderately-to-severely active Crohn's disease/ulcerative colitis

The ongoing phase 3b, randomized, double-blind, placebo (PBO)-controlled **APEX study (NCT04882098)** is further evaluating GUS effects on clinical and radiographic progression outcomes in **participants (pts) with active and erosive PsA**

APEX met primary (American College of Rheumatology ≥20% improvement [ACR20]) and major secondary (PsA-modified van der Heijde-Sharp [vdH-S] score change from baseline) endpoints, such that **GUS Q4W and Q8W demonstrated significantly higher rates of clinical improvement and significant inhibition of structural damage progression** vs PBO at Week(W)24[1]

Objectives

Evaluate consistency in GUS clinical response and radiographic progression inhibition across subgroups of pts of high clinical interest

APEX Study Design and Analysis Methods

Inclusion Criteria

- ✓ Biologic-naïve adults ≥18 years
- ✓ Active PsA ≥6 months (despite prior csDMARD, apremilast, NSAID); CASPAR criteria met
- ✓ ≥3 SJC; ≥3 TJC; CRP ≥0.3 mg/dL
- ✓ **≥2 erosive joints on radiographs of hands/feet**
- ✓ Active plaque psoriasis



Endpoints[a]	High Clinical Interest Baseline Subgroups[b]	Statistical Analysis
• Proportion achieving ACR20/50 response	**Demographics** (Sex, BMI) **PsA Characteristics** (Duration[c], SJC, TJC, CRP) **Medication Use** (MTX[d])	Pts who discontinued study intervention for any reason except natural disaster/ major disruption, initiated/ increased dose of csDMARD or corticosteroid, or initiated prohibited therapies prior to W24 were considered nonresponders[e]
• LSM change in PsA-modified vdH-S score		Based on an ANCOVA model[f]
• LSM change in PsA-modified vdH-S score	**Radiographic Features** (Total vdH-S, erosion, and JSN scores; joints with erosions/JSN)	Based on an ANCOVA model[f]

[a]Over 200 MI datasets. [b]29 subgroups were predefined to evaluate treatment consistency over baseline demographics (n=7), disease characteristics (n=12), medication use (n=5), and radiographic features (n=5); those of high clinical interest are reported here. [c]Predefined PsA duration subgroups categories were <1/≥1 to <3/≥3 years, however, <3/≥3 presented due to small sample size in <1 year category. [d]Predefined as csDMARD use at baseline, however, MTX component presented separately based on MTX representing the majority of csDMARD use at baseline. [e]Data impacted by, or missing due to, natural disaster/major disruption were imputed using MI; other missing data were imputed using NRI. [f]Explanatory model variables: baseline vdH-S score, treatment group, and randomization stratification level; data impacted by natural disaster/major disruption and missing data imputed using MI. **ACR**=American College of Rheumatology, **ANCOVA**=analysis of covariance, **BMI**=body mass index, **CASPAR**=CASsification criteria for Psoriatic Arthritis, **CRP**=C-reactive protein, **csDMARD**=conventional synthetic disease modifying antirheumatic drug, **F/U**=follow-up, **GUS**=guselkumab, **JSN**=joint space narrowing, **LSM**=least squares mean, **MI**=multiple imputation, **MTX**=methotrexate, **NRI**=nonresponder imputation, **NSAID**=nonsteroidal anti-inflammatory drug, **PBO**=placebo, **PsA**=psoriatic arthritis, **pts**=participants, **Q4W**=every 4 weeks, **Q8W**=every 8 weeks, **R**=randomization, **SJC**=swollen joint count, **TJC**=tender joint count, **vdH-S**=van der Heijde-Sharp, **W**=week.

Results

Similar proportions of pts comprised baseline characteristic subgroups across treatment arms

- Pts with active and erosive PsA: median disease duration=5 years, SJC=9, TJC=16, and CRP=0.8 mg/dL

Modified full analysis set[a]	PBO N=376	GUS Q4W N=273	GUS Q8W N=371	Total N=1020
Sex				
Male	57%	55%	54%	55%
Female	43%	45%	46%	45%
BMI, kg/m²				
Normal <25	26%	24%	27%	26%
Overweight ≥25 to <30	37%	37%	37%	37%
Obese ≥30	37%	39%	37%	37%
PsA disease duration, years				
<3	32%	33%	32%	32%
≥3	68%	67%	68%	68%
SJC (0–66)				
<10	52%	56%	46%	51%
10 to 15	23%	23%	33%	27%
>15	24%	21%	21%	22%
TJC (0–68)				
<10	21%	21%	17%	19%
10 to 15	24%	27%	29%	27%
>15	55%	52%	54%	54%
CRP, mg/dL				
<1	59%	61%	57%	59%
1 to <2	19%	20%	24%	21%
≥2	22%	19%	19%	20%
MTX use at baseline				
Yes	60%	59%	60%	60%
No	40%	41%	40%	40%

[a]All randomized pts except those from Ukraine sites rendered unable to support key study operations due to major disruptions (N=1020). ***BMI***=*body mass index,* ***CRP***=*C-reactive protein,* ***GUS***=*guselkumab,* ***MTX***=*methotrexate,* ***PBO***=*placebo,* ***PsA***=*psoriatic arthritis,* ***pts***=*participants,* ***Q4W***=*every 4 weeks,* ***Q8W***=*every 8 weeks,* ***SJC***=*swollen joint count,* ***TJC***=*tender joint count.*

GUS treatment effect on joint disease activity was consistent across subgroups

- Aligned with primary endpoint results, GUS-treated pts had approximately 2- to 4-times higher odds of achieving ACR20 response than PBO-treated pts



ACR=*American College of Rheumatology,* ***BMI***=*body mass index,* ***CI***=*confidence interval,* ***CRP***=*C-reactive protein,* ***GUS***=*guselkumab,* ***MTX***=*methotrexate,* ***OR***=*odds ratio,* ***PBO***=*placebo,* ***PsA***=*psoriatic arthritis,* ***pts***=*participants,* ***Q4W***=*every 4 weeks,* ***Q8W***=*every 8 weeks,* ***SJC***=*swollen joint count,* ***TJC***=*tender joint count,* ***W***=*week.*

GUS effect on the more stringent ACR50 response was also consistent across subgroups

- Aligned with overall ACR50 results, GUS-treated pts had approximately 2- to 6-times higher odds of achieving ACR50 response than PBO-treated pts



ACR=*American College of Rheumatology,* ***BMI***=*body mass index,* ***CI***=*confidence interval,* ***CRP***=*C-reactive protein,* ***GUS***=*guselkumab,* ***MTX***=*methotrexate,* ***OR***=*odds ratio,* ***PBO***=*placebo,* ***PsA***=*psoriatic arthritis,* ***pts***=*participants,* ***Q4W***=*every 4 weeks,* ***Q8W***=*every 8 weeks,* ***SJC***=*swollen joint count,* ***TJC***=*tender joint count,* ***W***=*week.*

Significant inhibition of structural damage progression with GUS was generally consistent across baseline pt subgroups

- Concordant with known risk factors, PBO-treated pts with SJC >15 & CRP ≥2 mg/dL exhibited notably higher degrees of radiographic progression, leading to even more robust GUS effects in these groups



[a]Interaction p-value <0.05 for SJC GUS Q4W and Q8W; TJC GUS Q8W; CRP GUS Q4W. ***BMI***=*body mass index,* ***CI***=*confidence interval,* ***CRP***=*C-reactive protein,* ***GUS***=*guselkumab,* ***LSM***=*least squares mean,* ***PBO***=*placebo,* ***PsA***=*psoriatic arthritis,* ***pt***=*participants,* ***Q4W***=*every 4 weeks,* ***Q8W***=*every 8 weeks,* ***SJC***=*swollen joint count,* ***TJC***=*tender joint count,* ***vdH-S***=*van der Heijde-Sharp,* ***W***=*week.*

Baseline radiographic joint damage was of moderate degree and similar across treatment groups

	PBO N=374	GUS Q4W N=271	GUS Q8W N=371	Total N=1016
Baseline Radiographic Features				
Total vdH-S score [0-528]	11.5 [5.0-27.5]	11.0 [4.5-26.5]	11.0 [4.5-25.0]	11.0 [5.0-26.5]
Erosion score [0-320]	6.0 [2.5-13.0]	5.5 [2.5-13.0]	6.0 [2.5-14.0]	6.0 [2.5-13.5]
JSN score [0-208]	5.0 [1.5-14.0]	5.5 [1.5-14.9]	5.0 [1.0-14.5]	5.0 [1.5-14.5]

Values are median [interquartile range].

Inhibition of structural damage progression with GUS was largely consistent regardless of baseline radiographic features

- PBO-treated pts with a vdH-S erosion score >6 and >4.5 erosive joints at baseline had the most radiographic progression at W24



[a]Interaction p-value <0.05 for erosion score GUS Q8W. ***CI***=*confidence interval,* ***GUS***=*guselkumab,* ***JSN***=*joint space narrowing,* ***LSM***=*least squares mean,* ***PBO***=*placebo,* ***pts***=*participants,* ***Q4W***=*every 4 weeks,* ***Q8W***=*every 8 weeks,* ***vdH-S***=*van der Heijde-Sharp,* ***W***=*week.*

PRESENTED AT: European Alliance of Associations for Rheumatology (EULAR) 2026; London, UK; June 3–6, 2026. **REFERENCES: 1.** Mease PJ, et al. *Ann Rheum Dis.* 2025;84(12):1983–1994. **ACKNOWLEDGMENTS:** Medical writing support was provided by Kelly Koch, PharmD of Johnson & Johnson, under the direction of the authors and in accordance with Good Publication Practice guidelines (*Ann Intern Med.* 2022;175:1298–1304). Layout design and formatting for this encore presentation were provided by Mugdha Rokade of SIRO Medical Writing Pvt Ltd, India (funded by Johnson & Johnson). This presentation was sponsored by Johnson & Johnson. **DISCLOSURES: PJM:** received grants from AbbVie, Acelyrin, Amgen, Bristol Myers Squibb, Eli Lilly, Johnson & Johnson, Novartis, and UCB; consulting fees from AbbVie, Acelyrin, Amgen, Bristol Myers Squibb, Century, Cullinan, Eli Lilly, Inmagene, Johnson & Johnson, Novartis, Pfizer, Spyre, Takeda, and UCB; and speaker fees from AbbVie, Amgen, Eli Lilly, Johnson & Johnson, Novartis, Pfizer, and UCB. **CTR:** received grant/research support from AbbVie, Amgen, UCB and consulting fees from AbbVie, Amgen, Eli Lilly, Gilead, Johnson & Johnson, Novartis, Pfizer, UCB. **LCC:** has received grants/research support from AbbVie, Amgen, Celgene, Eli Lilly, Johnson & Johnson, Novartis, Pfizer and UCB; worked as a paid consultant for AbbVie, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly, Gilead, Galapagos, Johnson & Johnson, MoonLake Immunotherapeutics, Novartis, Pfizer, and UCB; and has been paid as a speaker for AbbVie, Amgen, Biogen, Celgene, Eli Lilly, Galapagos, Gilead, GlaxoSmithKline, Johnson & Johnson, Medac, Novartis, Pfizer, and UCB. **APK, BZ, YJ, KB, KI, RB, and SDC:** are employees of Johnson & Johnson; employees may own stock/stock options in Johnson & Johnson. **KL:** is an employee of Johnson & Johnson and owns stock/stock options in Bristol Myers Squibb and Johnson & Johnson. **PR:** received consulting fees from AbbVie, Amgen, Bristol Myers Squibb, Celgene, Eli Lilly, Johnson & Johnson, Merck, Novartis, Pfizer, and UCB; meeting attendance/travel support from Johnson & Johnson; and research grants from Johnson & Johnson, and Novartis. **DvdH:** received consulting fees from AbbVie, Alfasigma, ArgenX, Bristol Myers Squibb, Eli Lilly, Grey-Wolf Therapeutics, Johnson & Johnson, Novartis, Pfizer, Takeda, UCB and is associate editor of Annals Rheumatic Diseases, and is an editorial board member Journal of Rheumatology, and director of Imaging Rheumatology BV. **Previously presented at:** Congress of Clinical Rheumatology – West (CCR-W); Huntington Beach, CA, USA; September 18–21, 2025.